Bicara Therapeutics stock gains on BofA initiation
Original source: https://www.investing.com/news/stock-market-news/bicara-therapeutics-stock-gains-on-bofa-initiation-93CH-4580489
Read More »InflaRx stock soars after positive Phase 2a data for INF904 drug
Original source: https://www.investing.com/news/stock-market-news/inflarx-stock-soars-after-positive-phase-2a-data-for-inf904-drug-93CH-4345710
Read More »Verastem stock rises after LGSOC treatment data published in medical journal
Original source: https://www.investing.com/news/stock-market-news/verastem-stock-rises-after-lgsoc-treatment-data-published-in-medical-journal-93CH-4132564
Read More »RNAZ Saw Record Share Volume Traded, As Investors Learned Short Interest Is 81.58% Of The Float
RNAZ Saw Record Share Volume Traded, As Investors Learned Short Interest Is 81.58% Of The Float. TransCode Therapeutics, Inc., (NASDAQ: RNAZ) saw a close up 45.45% to $1.12 amid investors learning that…
Read More »Q32 Bio: Oppenheimer slashes price target on mixed trial results
Original source: https://www.investing.com/news/stock-market-news/q32-bio-oppenheimer-slashes-price-target–on-mixed-trial-results-3765273
Read More »Eliem therapeutics executive sells over $9,000 in company stock
Original source: https://www.investing.com/news/stock-market-news/eliem-therapeutics-executive-sells-over-9000-in-company-stock-93CH-3626567
Read More »Sanofi: gemeinsame Zulassung mit Regeneron Pharmaceuticals für Blockbuster Dupixent
Fortschritte bei Lungenerkrankungen könnten die Sanofi-Aktie (SAN) beflügeln! Jetzt Swingtrade starten? Sanofi (SAN) – FR0000120578 Rückblick Mit einem Kursverlust von knapp 2.5 Prozent in den vergangenen sechs Monaten bewegt sich…
Read More »Pro Research: Wall Street dives into Regeneron’s robust prospects
Original source: https://www.investing.com/news/stock-market-news/pro-research-wall-street-dives-into-regenerons-robust-prospects-93CH-3279303
Read More »Pro Research: Wall Street eyes Gilead’s strategic moves in biopharma
Original source: https://www.investing.com/news/stock-market-news/pro-research-wall-street-eyes-gileads-strategic-moves-in-biopharma-93CH-3263753
Read More »MYMX Up 70% Today But The Company Intends To De-List And Go Private Soon.
MYMX Saw One Of The Biggest Runs On The Market Today But The Company Is Going Private, And Is Likely Just Seeing A Mercy Pump, Before No Longer Publicly Trading. Mymetics…
Read More »